Trevi Therapeutics Inc
TRVI11.460USD
+0.520+4.75%
Fechamento 02/06, 16:00（ET）Cotações atrasadas em 15 min
1.47BValor de mercado
PerdaP/L TTM
Mais detalhes de Trevi Therapeutics Inc Empresa
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in patients with idiopathic pulmonary fibrosis (IPF), chronic cough in patients with non-IPF interstitial lung disease, and refractory chronic cough. Haduvio is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed kappa-opioid receptor agonist and mu-opioid receptor antagonist. It has conducted a Phase II clinical trial and an open-label extension study of Haduvio in pruritus in patients with prurigo nodularis and a Phase IIb/III clinical trial. The Company’s Haduvio development programs include Chronic Cough in IPF Program, RCC Program, and Prurigo Nodularis Program. The Company’s subsidiary is Trevi Therapeutics Limited.
Informações de Trevi Therapeutics Inc
Código da empresaTRVI
Nome da EmpresaTrevi Therapeutics Inc
Data de listagemMay 07, 2019
CEOGood (Jennifer L)
Número de funcionários26
Tipo de títulosOrdinary Share
Fim do ano fiscalMay 07
Endereço195 Church Street
CidadeNEW HAVEN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal06510
Telefone12033042499
Sitehttps://www.trevitherapeutics.com/
Código da empresaTRVI
Data de listagemMay 07, 2019
CEOGood (Jennifer L)
Executivos da empresa Trevi Therapeutics Inc
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
352.49K
--
Dr. Thomas R. Sciascia, M.D.
Dr. Thomas R. Sciascia, M.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
214.43K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
213.31K
--
Dr. Farrell Simon, Pharm.D.
Dr. Farrell Simon, Pharm.D.
Chief Commercial Officer
Chief Commercial Officer
76.90K
+31250.00%
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Independent Director
Independent Director
6.35K
--
Dr. James V. (Jim) Cassella, Ph.D.
Dr. James V. (Jim) Cassella, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Mr. Dominick C. Colangelo
Mr. Dominick C. Colangelo
Independent Director
Independent Director
--
--
Mr. Edward T. Mathers
Mr. Edward T. Mathers
Independent Director
Independent Director
--
--
Ms. Anne M. Vanlent
Ms. Anne M. Vanlent
Independent Director
Independent Director
--
--
Jonathan Carlson
Jonathan Carlson
IR Contact Officer
IR Contact Officer
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Dr. David P. Meeker, M.D.
Dr. David P. Meeker, M.D.
Independent Chairman of the Board
Independent Chairman of the Board
352.49K
--
Dr. Thomas R. Sciascia, M.D.
Dr. Thomas R. Sciascia, M.D.
Co-Founder, Chief Scientific Officer
Co-Founder, Chief Scientific Officer
214.43K
--
Ms. Jennifer L. Good
Ms. Jennifer L. Good
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
213.31K
--
Dr. Farrell Simon, Pharm.D.
Dr. Farrell Simon, Pharm.D.
Chief Commercial Officer
Chief Commercial Officer
76.90K
+31250.00%
Mr. Michael Thomas (Mike) Heffernan
Mr. Michael Thomas (Mike) Heffernan
Independent Director
Independent Director
6.35K
--
Dr. James V. (Jim) Cassella, Ph.D.
Dr. James V. (Jim) Cassella, Ph.D.
Chief Development Officer
Chief Development Officer
--
--
Detalhamento da receita
Os dados relevantes ainda não foram divulgados pela empresa.
Os dados relevantes ainda não foram divulgados pela empresa.
Por Empresa
Por Região
Os dados relevantes ainda não foram divulgados pela empresa.
Distribuição de ações
Atualizado em: sex, 6 de fev
Atualizado em: sex, 6 de fev
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
New Enterprise Associates (NEA)
10.31%
Frazier Life Sciences Management, L.P.
8.00%
Rubric Capital Management LP
6.65%
BlackRock Institutional Trust Company, N.A.
5.75%
The Vanguard Group, Inc.
5.00%
Outro
64.28%
Investidores
Investidores
Proporção
New Enterprise Associates (NEA)
10.31%
Frazier Life Sciences Management, L.P.
8.00%
Rubric Capital Management LP
6.65%
BlackRock Institutional Trust Company, N.A.
5.75%
The Vanguard Group, Inc.
5.00%
Outro
64.28%
Tipos de investidores
Investidores
Proporção
Investment Advisor
29.97%
Investment Advisor/Hedge Fund
25.74%
Venture Capital
17.03%
Hedge Fund
16.44%
Private Equity
10.58%
Research Firm
5.74%
Individual Investor
0.76%
Pension Fund
0.36%
Bank and Trust
0.35%
Participação acionária institucional
Atualizado em: qui, 1 de jan
Atualizado em: qui, 1 de jan
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q4
299
136.48M
106.57%
+9.02M
2025Q3
272
116.14M
95.37%
+14.43M
2025Q2
232
94.28M
77.42%
+5.93M
2025Q1
226
89.66M
76.74%
+2.50M
2024Q4
177
80.67M
91.74%
+11.34M
2024Q3
156
59.14M
78.18%
-6.31M
2024Q2
148
56.93M
80.80%
-4.85M
2024Q1
147
52.57M
76.38%
-8.69M
2023Q4
131
54.54M
85.48%
-544.63K
2023Q3
124
54.64M
88.55%
-1.52M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
New Enterprise Associates (NEA)
13.22M
10.31%
+1.85M
+16.29%
Sep 30, 2025
Frazier Life Sciences Management, L.P.
10.26M
8%
--
--
Sep 30, 2025
Rubric Capital Management LP
8.53M
6.65%
--
--
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
7.37M
5.75%
+1.72M
+30.38%
Sep 30, 2025
The Vanguard Group, Inc.
5.81M
4.53%
+489.40K
+9.20%
Sep 30, 2025
Viking Global Investors LP
5.13M
4%
+3.59M
+232.40%
Sep 30, 2025
Vivo Capital, LLC
5.09M
3.97%
+606.76K
+13.52%
Sep 30, 2025
Marshall Wace LLP
4.84M
3.78%
+2.36M
+95.40%
Sep 30, 2025
AllianceBernstein L.P.
4.29M
3.35%
+11.10K
+0.26%
Sep 30, 2025
Morgan Stanley & Co. LLC
4.12M
3.21%
+3.26M
+379.72%
Sep 30, 2025
Ver Mais
ETFs Relacionados
Atualizado em: ter, 2 de dez
Atualizado em: ter, 2 de dez
Nome
Proporção
State Street SPDR S&P Pharmaceuticals ETF
1.91%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.36%
Invesco Dorsey Wright Healthcare Momentum ETF
1.3%
ALPS Medical Breakthroughs ETF
0.59%
Invesco Dorsey Wright SmallCap Momentum ETF
0.54%
Optimize Strategy Index ETF
0.37%
Vanguard US Momentum Factor ETF
0.22%
iShares Micro-Cap ETF
0.2%
Vanguard US Minimum Volatility ETF
0.18%
ProShares Ultra Nasdaq Biotechnology
0.14%
Ver Mais
State Street SPDR S&P Pharmaceuticals ETF
Proporção1.91%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proporção1.36%
Invesco Dorsey Wright Healthcare Momentum ETF
Proporção1.3%
ALPS Medical Breakthroughs ETF
Proporção0.59%
Invesco Dorsey Wright SmallCap Momentum ETF
Proporção0.54%
Optimize Strategy Index ETF
Proporção0.37%
Vanguard US Momentum Factor ETF
Proporção0.22%
iShares Micro-Cap ETF
Proporção0.2%
Vanguard US Minimum Volatility ETF
Proporção0.18%
ProShares Ultra Nasdaq Biotechnology
Proporção0.14%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
Data
Data ex-dividendo
Tipo
Proporção
Sem dados
